10.1002/bjs.1800691108 Br
Earlier SURMOUNT-1 data further reinforced these outcomes, with tirzepatide demonstrating weight loss of up to 22.5% of body weight over 72 weeks, the highest ever recorded for a pharmacological weight loss therapy at that time
They can also be caused by coronary heart disease or valvular heart disease
Heman P, Barcia C, Gmez A, Ros CM, Ros-Bernal F, Yuste JE, et al
This has led to a surge in interest comparing tirzepatide, the reigning champion of metabolic pharmacotherapy, against retatrutide, the highly anticipated challenger
(2024) reviewed the heterogeneity in lean mass loss across GLP-1 studies and found that lean mass reductions ranged from 15% to 60% of total weight lost , depending on the drug, population, dose, and measurement methodology